‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars
Senior VP And Head Of Marketing Kevin Byoung Seo Choi Talks To Generics Bulletin
• By David Wallace
Analysts estimate that BioFactura's ustekinumab represents a $50m market opportunity • Source: Shutterstock 
